Exigence Technologies

mountain river Rolls of the polypropylene workpiece scrub nurse praparing instruments for open heart operation Sport - runner running and sprinting in desert. Athlete man during sprint run at great speed. Fitness man wearing compression clothes. Serious clinician studying chemical element in laboratory

 Next-Generation Antimicrobial Technology

Exigence has created the world’s most advanced family of germ fighting compounds. Our patented biocides draw microbes in and then eliminate them using a breakthrough composite antimicrobial technology. This combination technology has unique synergistic characteristics that ensure pathogens do not survive or develop microbial resistance.

What Drives Us

At Exigence Technologies, we care about preventing the spread of infectious diseases, and we are particularly concerned about the increasing resistance to antibiotics being observed in once-treatable bacterial infections. This is why we’ve created a whole new class of antimicrobial compounds that have the potential to make the environmental surfaces around us part of the solution to the antibiotic resistance problem. Our family of novel composite biocides has something to offer that the world has never seen before – complete reduction of bacteria on any treated surface within minutes, while other treated surfaces take hours or days to achieve the same effect. Our compounds will not migrate out of the products to poison food, groundwater, or people and are more resistant to organic loads than most compounds, making our products more useful for real life disinfection challenges.

Rigorous lab studies have shown that our technology does not promote resistance in bacteria. This is important because many of the non-oxidizing antimicrobial technologies on the market are pushing us closer to a post-antibiotic era. Our technology’s mode of action has been observed in one of our component compounds and in over 180 years of use, this compound has never induced microbial resistance.  This fact, along with our laboratory test results, gives us confidence that this promising advantage will stand the test of time.

Exigence Technologies is headquartered in the heart of Canada, but our technology has a global reach. Our firm’s scientific and R&D capabilities make us an ideal development partner for companies who want to build high performance antimicrobial products, particularly where performance and safety are tantamount concerns. Our team and our capacity is growing. There are many problems humanity will be forced to deal with in the next century, but at Exigence Technologies, we aim to remove one of these problems from the list.

Major benefits of our advanced antimicrobial technology:

Nurse looking at you (close-up)

  • Synergistic performance (better than a formulation) due to their unique composite chemical structure
  • 6-log (99.9999%) reduction in microbes in 5-20 minutes when bonded to a substrate.  Competitor products take hours to days to achieve the same level of efficacy.
  • Rechargeable function – once bonded to a substrate, the antimicrobial effect can be recharged using a very simple procedure
  • Does not induce microbial resistance
  • Penetrates through heavy organic loads including manure and protein layers
  • Non-corrosive
  • Environmentally friendly
  • Non-leaching when bonded to a substrate

Why the world needs a better antimicrobial technology:

Bacteria are a natural and often necessary part of our world, and sometimes we forget the benefits that microbes bring us.  However, as the human population increases the demands on its environment, we find that in a broad range of situations our species is coming into conflict with the smallest members of our planet.  Microbes cause thirty percent of the world’s food to spoil before it can be consumed, but research has shown that microbe-free food packaging can help alleviate this problem.  Millions of people don’t have access to clean water, but advanced antimicrobial technology can help solve this issue and prevent unnecessary disease.  Viruses wreak havoc in the global livestock industry, but pharmaceutical companies cannot develop effective vaccines rapidly enough to prevent the loss of poultry and swine herds.  All of this is before we consider the toll on human health –

Over 220,000 Canadians, 1.7 million Americans and 4.1 million Europeans acquire a Healthcare Associated Infection (HAI) every year, and more than 147,000 die as a result. HAIs are caused by the spread of drug resistant bacteria like Methicillin Resistant Staphylococcus Aureus (MRSA) and Vancomycin Resistant Enterococcus (VRE) in the healthcare setting. In spite of massive hand-washing initiatives and hard surface cleaning, hospitals and other healthcare institutions have been unable to contain the spread of drug-resistant pathogens.

blue cells

Bacteria that are not rapidly or completely eliminated by antibiotics or other antimicrobial technologies become difficult to kill because they are able to mutate into resistant forms. Organic compounds, quaternary ammonium compounds and silver nano-technologies have been shown to have the potential to exacerbate this problem. Exigence Technologies has an antimicrobial technology solution that overcomes the resistance issue, and exceeds benchmarks set out in industry-standard microbial mutation tests.

While governments and public health agencies sound the alarm over the potential for a post-antibiotic era, Exigence Technologies is offering a better path forward. Our compounds can be used as proactive solutions to several pressing animal health and public health problems, because an ounce of prevention is still worth a pound of cure.